Stay updated with breaking news from Alber Bourla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (Sputnik) - The pharmaceutical companies Pfizer and BioNTech said in a press release that they are seeking Emergency Use Authorization for their... 02.02.2022, Sputnik International
INDIA New England News By Arul Louis New York– Pfizer is discussing expedited approval of its Covid-19 vaccine with the Indian government, company CEO Alber Bourla said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic. “We are currently discussing with Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country,” he said in a video posted on the company website. He pledged to send enough medicines over the next 90 days “to ensure that every Covid-19 patient in every public ho...
NEW YORK — India's External Affairs Minister S. Jaishankar and U.S. Secretary of State Anthony Blinken have discussed increasing Covid-19 vaccine production capacity during their meeting in London.
Pfizer in talks with India on vax approval, says CEO Tue, May 4 2021 10:21 IST | 14 Views Pfizer in talks with India on vax approval, says CEO. Image Source: IANS New York, May 4 : Pfizer is discussing expedited approval of its Covid-19 vaccine with the Indian government, company CEO Alber Bourla said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic. "We are currently discussing with Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country," he said in a video posted on the company...
Photo Credit: IANS IANSLive New York, May 4 (IANS) Pfizer is discussing expedited approval of its Covid-19 vaccine with the Indian government, company CEO Alber Bourla said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 04-May-2021